Understanding genetic basis for heart disease opens up opportunity for gene editing solution

Understanding genetic basis for heart disease opens up opportunity for gene editing solution

Leaps |
Later this year, Verve Therapeutics of Cambridge, Ma., will initiate Phase 1 clinical trials to test VERVE-101, a new medication ...